Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Evans will deliver a presentation on January 13, 2025, at 1:30 p.m. PT in San Francisco. The presentation will be accessible via live webcast on the company's website investor section at www.beamtx.com and will remain available for 60 days after the event.

News Market Reaction – BEAM

-1.21%

-1.21% Session move

In the trading session that priced this news, BEAM declined 1.21%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco.

A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning
Beam Therapeutics
hmanning@beamtx.com 

FAQ

When is Beam Therapeutics (BEAM) presenting at the 2025 J.P. Morgan Healthcare Conference?

Beam Therapeutics will present on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco.

How can investors watch Beam Therapeutics' (BEAM) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast in the investor section of Beam's website at www.beamtx.com. The recording will be archived for 60 days following the presentation.

Who will represent Beam Therapeutics (BEAM) at the 2025 J.P. Morgan Healthcare Conference?

John Evans, the chief executive officer of Beam Therapeutics, will represent the company at the conference.

How long will Beam Therapeutics' (BEAM) J.P. Morgan Conference presentation be available online?

The presentation webcast will be archived and available for 60 days following the live presentation on Beam's website.